What Is It and How Does It Work?
Deuruxolitinib is a twice-daily oral pill (8 mg dose) approved specifically for adults suffering from severe alopecia areata. This chronic autoimmune condition occurs when the body’s protective immune cells mistakenly attack healthy hair follicles, causing severe local inflammation that forces hair to fall out.
The treatment works through a precise biological process called Oral Selective Janus Kinase 1 and 2 (JAK1/JAK2) Inhibition:
-
The Overactive Pathway: In autoimmune alopecia, inflammatory signals use specific enzyme pathways—specifically JAK1 and JAK2—to broadcast constant “attack” instructions directly to your hair follicles.
-
Silencing the Alarm: Deuruxolitinib acts as a chemical signal blocker. By binding to and disabling the JAK1 and JAK2 enzymes, it jams the transmission of these inflammatory signals exactly where the attack happens.
-
Restoring Growth: With the inflammatory assault stopped, the hair follicles can safely exit their forced dormant state and return to their natural job of growing hair.
The Science: High-Density Regrowth Confirmed by the SALT Score
The UK MHRA’s approval is supported by robust data from two randomized, double-blind, placebo-controlled Phase 3 clinical trials: THRIVE-AA1 and THRIVE-AA2. To precisely measure how well the drug worked, clinical investigators relied on the standard SALT score.
What is the SALT Score? The Severity of Alopecia Tool (SALT) score is the standard measurement dermatologists use to track the exact percentage of hair loss on a patient’s scalp.
100 represents absolute, 100% hair loss across the entire scalp.
0 represents a completely full head of hair with 0% hair loss.
In clinical studies, the standard benchmark for success is reaching a SALT score of 20 or less (often written as SALT20). This means a patient has successfully regrown hair to cover 80% or more of their scalp.
The clinical results from the Phase 3 studies demonstrated highly significant regrowth:
-
80% Scalp Coverage (SALT20): Around 30% of severe alopecia patients receiving the approved 8 mg twice-daily dose achieved at least 80% scalp hair coverage (SALT ≤ 20) by Week 24, compared to less than 1% of patients in the placebo group.
-
90% Scalp Coverage (SALT10): An impressive 23% of participants achieved a near-total regrowth of 90% or more scalp hair coverage (SALT ≤ 10) in the same 24-week period, compared to virtually zero in the placebo arm.
-
Rapid Onset of Efficacy: Regrowth progress was clinically visible early on, with a subset of patients showing significant improvement in hair density and coverage as early as Week 8 of treatment.
Read next
Whats the best shampoo for hair loss?
-
Favorable Safety and Tolerability: Deuruxolitinib was generally well tolerated. The most common side effects reported were mild-to-moderate headaches (experienced by 12.4% of users) and acne (experienced by 10.0%), with very few patients needing to discontinue their treatment.
“This approval gives adults with alopecia areata another potential treatment option to help manage their condition. As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review.” — Julian Beach, MHRA Executive Director of Healthcare Quality and Access.
When Will It Be Available?
-
Regulatory Status: Following its FDA approval in the United States, deuruxolitinib was officially approved by the UK’s MHRA on March 10, 2026, under the brand name Leqselvi.
-
UK Availability: With marketing authorization secured, healthcare providers in the UK can now officially prescribe Leqselvi to adult patients. The recommended clinical dose is a single 8 mg tablet taken twice daily.
How you can benefit from this treatment now
If you are struggling with severe patchy or total autoimmune hair loss, the official UK MHRA approval of Leqselvi provides actionable avenues today:
-
Schedule a Dermatologist Consultation: Because Leqselvi is a prescription-only medication, your first step is to consult with a specialist dermatologist. They can evaluate your clinical history, confirm whether your hair loss is driven by alopecia areata, and perform the necessary baseline tests (including checking for your CYP2C9 gene type, which influences how your liver processes the drug) before initiating the twice-daily regimen.
-
Evaluate Other Approved Options: The approval of Leqselvi expands a rapidly maturing class of JAK inhibitors. If you reside outside of the UK or are exploring alternative regimens, discuss other approved JAK inhibitors—such as Olumiant (baricitinib) and Litfulo (ritlecitinib)—to determine which molecular blocker aligns best with your health profile and treatment goals.
-
Understand the Long-Term Routine: It is important to know that Leqselvi treats the symptoms of autoimmune hair loss but does not cure the underlying condition. Clinical data indicates that if you stop taking the medication, the immune system may resume its attack, leading to a recurrence of shedding. Preparing for a consistent, long-term treatment routine is key to maintaining your newly regrown hair.
Sources: